The Scripps Research Institute is an educational institution that offers graduate programs and postdoctoral fellows in biological and chemical sciences. It also provides programs for high school and middle school students, teachers, and undergraduates. The institution was formerly known as Scripps Institutions of Medicine and Science. The Scripps Research Institute was founded in 1991 and is based in La Jolla, California.
10550 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1991
The Scripps Research Institute and the University of California Develops a Powerful New System
Dec 19 14
The Scripps Research Institute (TSRI) and the University of California (UC) San Diego have developed a powerful new system for studying how proteins and other biological molecules form and lose their natural folded structures. Using the new system, researchers can force a sample of molecules to unfold and refold by boosting and then dropping the temperature, so quickly that even some of the fastest molecular folding events can be tracked.
The Scripps Research Institute Reports Positive New Clinical Data on Drug Candidate
Oct 27 14
The Scripps Research Institute reported positive new clinical data were released on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI). According to results released from a Phase 2 study of 199 patients with active, moderate to severe disease, the drug candidate RPC1063 has potential to significantly improve the treatment paradigm for ulcerative colitis patients. The latest results show that, after eight weeks of treatment with a 1 mg dose of RPC1063, 16.4% of patents were in clinical remission, as compared to 6.2% of patients on placebo. The clinical trial, sponsored by Receptos Inc., the San Diego biotechnology company now developing the drug, also showed that RPC1063 was generally well tolerated. Ulcerative colitis is a chronic condition that involves inflammation and sores in the inner lining of the digestive tract. Ulcerative colitis is an inflammatory bowel disease, which, along with Crohn's disease, affects more than one million people nationwide, according to the U.S. Centers for Disease Control and Prevention. Some people have mild disease, while others are affected with life-threatening complications. While existing medications for ulcerative colitis do help some patients, 23 to 45% of ulcerative colitis sufferers progress and eventually require surgical removal of all or part of the colon, according to the Crohn's and Colitis Foundation of America. The drug candidate RPC1063 was derived from a screening "hit" from the National Institutes of Health molecular library at Scripps Florida's Molecular Screening Center, using assay technology from the Rosen lab in La Jolla. The Roberts and Rosen labs then developed significant medicinal chemistry to turn that hit into a validated lead, and then ultimately a drug candidate. TSRI then licensed the compound to Receptos, which is developing RPC1063 for approval by the U.S. Food and Drug Administration. The latest results come from Receptos's multi-national, multi-center, double-blind, randomized, placebo-controlled study investigating the effect of two active doses of RPC1063 versus placebo for the treatment of moderately to severely active ulcerative colitis.
Scripps Florida Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM
Oct 11 14
Scripps Florida Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Dawn Johnson, Senior Director, Florida Operations.